All In Biotech

Drug Trial Radar · NCT01161940

Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions

A Two-way Crossover Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Nizatidine 300 mg Capsules in Healthy Human Subjects Under Fasting Conditions

Last checked: Nov 20, 2026Latest source record: Jul 14, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Jul 2004

Primary completion

Sep 2004

Study completion Sep 2004

Sponsor

Sponsor type
Industry
First posted
Jul 14, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a bioequivalence study of nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited under fasting conditions

Conditions

  • Healthy

Interventions

  • NizatidineDrug

    Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited

  • AxidDrug

    Axid 300 mg Capsules of Reliant Pharmaceuticals, US

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bioequivalence based on Cmax and AUC parametersTime frame: 3 Months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.